|Mr. Geoffrey Paul Kempler B.Sc., B.Sc||Co-Founder & Non-Exec. Chairman||336.05k||N/A||1955|
|Dr. David A. Stamler||CEO, Chief Medical Officer & Sr. VP of Clinical Devel.||471.27k||N/A||1961|
|Ms. Kathryn J. E. Andrews||Chief Financial Officer||194.29k||N/A||1967|
|Dr. Rudolph Emile Tanzi||Chief Scientific Advisor and Member of R&D Advisory Board||N/A||N/A||N/A|
|Dr. Steven D. Targum||Chief Medical Advisor||N/A||N/A||N/A|
|Dr. Robert Cherny||Head of Research||N/A||N/A||N/A|
|Mr. Phillip Allen Hains||Company Sec.||N/A||N/A||1959|
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Alterity Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.